Current Beat
May | 2 | 2024
Press Release
Remix Therapeutics™ Announces First Patients Dosed in Two Phase 1 Clinical Trials Investigating REM-422 for Treatment of Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS)
REM-422 granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of ACC and AML Advances REM-422, an oral small molecule messenger RNA (mRNA) degrader to two clinical studies to evaluate safety and clinical activity in ACC and AML/MDS Watertown, Mass. (May 2, 2024) – Remix Therapeutics (Remix), a […]
/
Media Contact
